← Leaderboards
Elizabeth P Henske
Brigham And Women'S Hospital
$25,563,270
Attributed
$29,332,506
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,332,506 · 16
By mechanism
R01$22,185,536 · 12
U01$5,672,132 · 1
RC1$996,026 · 1
R21$462,812 · 1
R13$16,000 · 1
Top collaborators
- Carmen Priolo6 shared
- Wei Shi4 shared
- Souheil El-Chemaly3 shared
- David J. Kwiatkowski2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- David J. Kwiatkowski$31,996,627
- Carmen Priolo$3,651,366
- Karen M Cichowski$14,585,944
- Chin-Lee Wu$1,488,018
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTsc2 GeneLeadIn VivoTuberous Sclerosis Protein ComplexTumorPathway InteractionsPathogenesisIn VitroProteinsMouse ModelTherapeutic TargetLymphangioleiomyomatosisMutationGeneticTuberous SclerosisCystCell GrowthMetabolismRenal AngiomyolipomaAngiomyolipomaFrap1 GeneSirolimusKidney
Grant awards (74)
Mechanisms of immunosuppression in the development and progression of renal disease in Tuberous Sclerosis Complex$523,592
R01 · FY2025 · DK · contact PI
Role of TFEB and TFE3 in Tuberous Sclerosis Complex (TSC) Kidney Disease$384,263
R01 · FY2025 · DK · contact PI
The Molecular and Genetic Pathogenesis of LAM$668,977
U01 · FY2024 · HL · contact PI
Mechanisms of immunosuppression in the development and progression of renal disease in Tuberous Sclerosis Complex$506,772
R01 · FY2024 · DK · contact PI
Role of TFEB and TFE3 in Tuberous Sclerosis Complex (TSC) Kidney Disease$368,893
R01 · FY2024 · DK · contact PI
The Molecular and Genetic Pathogenesis of LAM$685,620
U01 · FY2023 · HL · contact PI
Mechanisms of immunosuppression in the development and progression of renal disease in Tuberous Sclerosis Complex$539,046
R01 · FY2023 · DK · contact PI
Role of the Lysosome in the Pathogenesis and Therapy of LAM$439,461
R01 · FY2023 · HL · contact PI
Role of TFEB and TFE3 in Tuberous Sclerosis Complex (TSC) Kidney Disease$384,263
R01 · FY2023 · DK · contact PI
The Molecular and Genetic Pathogenesis of LAM$690,610
U01 · FY2022 · HL · contact PI
Role of the Lysosome in the Pathogenesis and Therapy of LAM$439,461
R01 · FY2022 · HL · contact PI
The Metabolic Pathogenesis of Chromophobe Renal Cell Carcinoma$399,620
R01 · FY2022 · CA · contact PI
Role of TFEB and TFE3 in Tuberous Sclerosis Complex (TSC) Kidney Disease$384,263
R01 · FY2022 · DK · contact PI
Pathogenic Mechanisms of Pulmonary Lymphangioleiomyomatosis$341,355
R01 · FY2022 · HL
Pathogenic Mechanisms of Pulmonary Lymphangioleiomyomatosis$647,500
R01 · FY2021 · HL
The Molecular and Genetic Pathogenesis of LAM$615,445
U01 · FY2021 · HL · contact PI
Role of the Lysosome in the Pathogenesis and Therapy of LAM$439,461
R01 · FY2021 · HL · contact PI
The Metabolic Pathogenesis of Chromophobe Renal Cell Carcinoma$407,775
R01 · FY2021 · CA · contact PI
The Molecular and Genetic Pathogenesis of LAM$877,667
U01 · FY2020 · HL · contact PI
Pathogenic Mechanisms of Pulmonary Lymphangioleiomyomatosis$647,500
R01 · FY2020 · HL
Role of the Lysosome in the Pathogenesis and Therapy of LAM$439,461
R01 · FY2020 · HL · contact PI
The Metabolic Pathogenesis of Chromophobe Renal Cell Carcinoma$375,563
R01 · FY2020 · CA · contact PI
Pathogenic Mechanisms of Pulmonary Lymphangioleiomyomatosis$664,875
R01 · FY2019 · HL
The Metabolic Pathogenesis of Chromophobe Renal Cell Carcinoma$411,468
R01 · FY2019 · CA · contact PI
Induction of Oncogenic mircoRNA by rapamycin: Role in TSC Therapy$383,333
R01 · FY2019 · DK · contact PI
The Metabolic Pathogenesis of Chromophobe Renal Cell Carcinoma$36,579
R01 · FY2019 · CA · contact PI
The Molecular and Genetic Pathogensis of LAM$686,741
U01 · FY2018 · HL · contact PI
The Metabolic Pathogenesis of Chromophobe Renal Cell Carcinoma$426,489
R01 · FY2018 · CA · contact PI
Induction of Oncogenic mircoRNA by rapamycin: Role in TSC Therapy$383,333
R01 · FY2018 · DK · contact PI
The Molecular and Genetic Pathogensis of LAM$692,126
U01 · FY2017 · HL · contact PI
Induction of Oncogenic mircoRNA by rapamycin: Role in TSC Therapy$383,333
R01 · FY2017 · DK · contact PI
The Molecular and Genetic Pathogensis of LAM$754,946
U01 · FY2016 · HL · contact PI
Metabolic Reprogramming in LAM: Novel Therapeutic Strategies$422,480
R01 · FY2016 · HL · contact PI
Induction of Oncogenic mircoRNA by rapamycin: Role in TSC Therapy$383,333
R01 · FY2016 · DK · contact PI
Roles of autophagy-mediated pathways in the pathogenesis and treatment of TSC$367,184
R01 · FY2016 · DK · contact PI
Metabolic Reprogramming in LAM: Novel Therapeutic Strategies$416,142
R01 · FY2015 · HL · contact PI
Induction of Oncogenic mircoRNA by rapamycin: Role in TSC Therapy$383,163
R01 · FY2015 · DK · contact PI
Roles of autophagy-mediated pathways in the pathogenesis and treatment of TSC$366,701
R01 · FY2015 · DK · contact PI
Metabolic Reprogramming in LAM: Novel Therapeutic Strategies$413,573
R01 · FY2014 · HL · contact PI
Roles of autophagy-mediated pathways in the pathogenesis and treatment of TSC$365,735
R01 · FY2014 · DK · contact PI
Metabolic Reprogramming in LAM: Novel Therapeutic Strategies$400,868
R01 · FY2013 · HL · contact PI
Roles of autophagy-mediated pathways in the pathogenesis and treatment of TSC$352,002
R01 · FY2013 · DK · contact PI
Roles of autophagy-mediated pathways in the pathogenesis and treatment of TSC$364,286
R01 · FY2012 · DK · contact PI
Summit on Drug Discovery in Tuberous Sclerosis Complex and Related Disorders$16,000
R13 · FY2011 · NS · contact PI
The Lymphangioleiomyomatosis (LAM)Genome Atlas$496,038
RC1 · FY2010 · HL
Roles of Tuberin (TSC2), Hamartin (TSC1), and Rheb in Renal Cyst Pathogenesis$430,785
R01 · FY2010 · DK · contact PI
Regulation of Estrogen Signaling by Tuberin and Rheb$424,295
R01 · FY2010 · HL · contact PI
The Lymphangioleiomyomatosis (LAM)Genome Atlas$499,988
RC1 · FY2009 · HL
Roles of Tuberin (TSC2), Hamartin (TSC1), and Rheb in Renal Cyst Pathogenesis$432,908
R01 · FY2009 · DK · contact PI
Regulation of Estrogen Signaling by Tuberin and Rheb$421,968
R01 · FY2009 · HL · contact PI
Regulation of Estrogen Signaling by Tuberin and Rheb$415,103
R01 · FY2008 · HL · contact PI
Mechanisms of Renal Tumorigenesis in Tuberous Sclerosis$240,491
R01 · FY2008 · DK · contact PI
Mechanisms of Renal Tumorigenesis in Tuberous Sclerosis$67,760
R01 · FY2008 · DK · contact PI
Regulation of Estrogen Signaling by Tuberin and Rheb$415,103
R01 · FY2007 · HL · contact PI
A Schizosaccharomyces pombe Model of Birt-Hogg-Dube Syndrome$249,062
R21 · FY2007 · HL · contact PI
Mechanisms of Renal Tumorigenesis in Tuberous Sclerosis$246,149
R01 · FY2007 · DK · contact PI
Mechanisms of Renal Tumorigenesis in Tuberous Sclerosis$68,393
R01 · FY2007 · DK · contact PI
Regulation of Estrogen Signaling by Tuberin and Rheb$427,500
R01 · FY2006 · HL · contact PI
Molecular Basis of Lymphangiomyomatosis$413,995
R01 · FY2006 · HL · contact PI
Mechanisms of Renal Tumorigenesis in Tuberous Sclerosis$253,500
R01 · FY2006 · DK · contact PI
A Schizosaccharomyces pombe Model of Birt-Hogg-Dube Syndrome$213,750
R21 · FY2006 · HL · contact PI
Molecular Basis of Lymphangiomyomatosis$425,000
R01 · FY2005 · HL
Molecular Basis of Lymphangiomyomatosis$382,500
R01 · FY2004 · HL
Molecular Basis of Lymphangiomyomatosis$342,333
R01 · FY2003 · HL
MECHANISMS OF RENAL MALIGNANCY IN TUBEROUS SCLEROSIS$336,000
R01 · FY2003 · DK
MECHANISMS OF RENAL MALIGNANCY IN TUBEROUS SCLEROSIS$62,839
R01 · FY2003 · DK
MECHANISMS OF RENAL MALIGNANCY IN TUBEROUS SCLEROSIS$336,000
R01 · FY2002 · DK
MOLECULAR BASIS OF LYMPHANGIOMYOMATOSIS$174,579
R01 · FY2002 · HL
MECHANISMS OF RENAL MALIGNANCY IN TUBEROUS SCLEROSIS$61,158
R01 · FY2002 · DK
MECHANISMS OF RENAL MALIGNANCY IN TUBEROUS SCLEROSIS$342,666
R01 · FY2001 · DK
MOLECULAR BASIS OF LYMPHANGIOMYOMATOSIS$292,902
R01 · FY2001 · HL
MECHANISMS OF RENAL MALIGNANCY IN TUBEROUS SCLEROSIS$86,417
R01 · FY2001 · DK
MECHANISMS OF RENAL MALIGNANCY IN TUBEROUS SCLEROSIS$259,250
R01 · FY2000 · DK
MOLECULAR BASIS OF LYMPHANGIOMYOMATOSIS$232,816
R01 · FY2000 · HL